Objective:To summarize the clinical characteristics of ulcerative colitis (UC) with primary sclerosing cholangitis (PSC) .Methods:The clinical characteristics, diagnosis and treatment of 6 UC patients with PSC admitted to Sir Run Run Shaw Hospital affiliated to Zhejiang University School of Medicine from May 2017 to May 2022 were analyzed retrospectively. Meanwhile "ulcerative colitis", "primary sclerosing colangitis" were used as retrieval words to search associated literatures from CNKI, Wanfang Data, and PubMed databases as of August 2022. Relevant literatures were reviewed and summarized.Results:There were 6 UC patients complicated with PSC, included 4 males and 2 females. Four UC cases were diagnosed before PSC and other 2 cases were diagnosed simultaneously. Six cases were all extensive colonic type (E3), 2 patients were rectal sparing, and 4 patients had backwash ileitis. Five patients had elevated alkaline phosphatase (AKP) levels. All the patients received oral treatment with ursodeoxycholic acid (UDCA). Two patients with concurrent cholangiocarcinoma died within one year of follow-up. A total of 75 relevant literatures were retrieved.Conclusions:Patients with UC complicated with PSC are often diagnosed with UC before PSC, and PSC is often discovered due to abnormal liver function. The main clinical manifestations include jaundice, abdominal pain and diarrhea, and some may be accompanied by symptoms such as fever, vomiting, and fatigue. There are clinical characteristics such as elevated AKP, pancolitis, rectal sparing, and backwash ileitis. UC complicated with PSC is more likely to develop cholangiocarcinoma.

This article reports a rare Crohn′s disease (CD) case complicated with deep vein thrombosis and Guillain-Barre syndrome (GBS). Through the diagnosis and treatment of the multidisciplinary team, the condition of patient is relieved with no recurrence. Prevention of venous thromboembolism, rare extraintestinal manifestations and rare side adverse of anti-tumor necrosis factor-α monoclonal antibodies and their mechanisms in CD patients were discussed for reference.

Objective:To summarize the clinical characteristics of ulcerative colitis (UC) with primary sclerosing cholangitis (PSC) .Methods:The clinical characteristics, diagnosis and treatment of 6 UC patients with PSC admitted to Sir Run Run Shaw Hospital affiliated to Zhejiang University School of Medicine from May 2017 to May 2022 were analyzed retrospectively. Meanwhile "ulcerative colitis", "primary sclerosing colangitis" were used as retrieval words to search associated literatures from CNKI, Wanfang Data, and PubMed databases as of August 2022. Relevant literatures were reviewed and summarized.Results:There were 6 UC patients complicated with PSC, included 4 males and 2 females. Four UC cases were diagnosed before PSC and other 2 cases were diagnosed simultaneously. Six cases were all extensive colonic type (E3), 2 patients were rectal sparing, and 4 patients had backwash ileitis. Five patients had elevated alkaline phosphatase (AKP) levels. All the patients received oral treatment with ursodeoxycholic acid (UDCA). Two patients with concurrent cholangiocarcinoma died within one year of follow-up. A total of 75 relevant literatures were retrieved.Conclusions:Patients with UC complicated with PSC are often diagnosed with UC before PSC, and PSC is often discovered due to abnormal liver function. The main clinical manifestations include jaundice, abdominal pain and diarrhea, and some may be accompanied by symptoms such as fever, vomiting, and fatigue. There are clinical characteristics such as elevated AKP, pancolitis, rectal sparing, and backwash ileitis. UC complicated with PSC is more likely to develop cholangiocarcinoma.

This article reports a rare Crohn′s disease (CD) case complicated with deep vein thrombosis and Guillain-Barre syndrome (GBS). Through the diagnosis and treatment of the multidisciplinary team, the condition of patient is relieved with no recurrence. Prevention of venous thromboembolism, rare extraintestinal manifestations and rare side adverse of anti-tumor necrosis factor-α monoclonal antibodies and their mechanisms in CD patients were discussed for reference.